NASDAQ · XERS
Healthcare · Biotechnology
$10.35
Up+$0.11 (+1.06%)
Updated Nov 4, 2026, 11:00 PM
SID Score
7.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · XERS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
XERS closed at $10.35 after 21 trading sessions, up 2.78% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $10.17 | $10.56 | $10.17 | $10.35 | 3.29M |
| Nov 2, 2026 | $10.71 | $10.72 | $10.08 | $10.17 | 2.31M |
| Oct 30, 2026 | $10.81 | $10.8782 | $10.515 | $10.71 | 1.55M |
| Oct 29, 2026 | $10.80 | $10.945 | $10.705 | $10.75 | 1.75M |
| Oct 28, 2026 | $10.45 | $10.75 | $10.39 | $10.64 | 1.45M |
| Oct 27, 2026 | $10.16 | $10.485 | $10.10 | $10.45 | 1.52M |
| Oct 26, 2026 | $10.22 | $10.405 | $10.12 | $10.21 | 1.91M |
| Oct 23, 2026 | $10.85 | $10.85 | $10.06 | $10.20 | 2.37M |
| Oct 22, 2026 | $10.81 | $10.98 | $10.67 | $10.86 | 1.41M |
| Oct 21, 2026 | $11.14 | $11.275 | $10.7701 | $10.785 | 1.68M |
| Oct 20, 2026 | $11.005 | $11.35 | $10.9639 | $11.13 | 2.9M |
| Oct 19, 2026 | $10.34 | $11.415 | $10.34 | $10.95 | 4.34M |
| Oct 16, 2026 | $10.04 | $10.33 | $9.8401 | $10.31 | 2.29M |
| Oct 15, 2026 | $9.77 | $10.18 | $9.76 | $10.07 | 1.94M |
| Oct 14, 2026 | $10.08 | $10.39 | $9.73 | $9.77 | 2.37M |
| Oct 13, 2026 | $10.41 | $10.50 | $10.15 | $10.20 | 2.22M |
| Oct 12, 2026 | $10.465 | $10.55 | $10.325 | $10.46 | 1.33M |
| Oct 9, 2026 | $10.15 | $10.60 | $10.07 | $10.48 | 3M |
| Oct 8, 2026 | $10.10 | $10.35 | $10.00 | $10.19 | 1.98M |
| Oct 7, 2026 | $10.00 | $10.27 | $9.91 | $10.11 | 2.22M |
| Oct 6, 2026 | $10.23 | $10.325 | $9.90 | $10.07 | 2.4M |
The latest Smart Investors Daily articles mentioning XERS.
Company
Market Activity
Research & News
XERS research
Company profile and research snapshot.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | Barclays | Overweight | — |
| Sep 10, 2026 | Leerink Partners | Outperform | — |
| Aug 20, 2026 | Barclays | Overweight | — |
| Mar 2, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Nov 2, 2026
CHICAGO, November 02, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced the appointment of Menassie M. Taddese to its Board of Directors, effective today. Taddese will also serve on the Board’s Audit Committee.
Yahoo · Oct 22, 2026
CHICAGO, October 22, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced it will release its financial results and business highlights for the third quarter ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 5, 2026. Management will host a conference call
Yahoo · Oct 15, 2026
CHICAGO, October 15, 2026--XERIS BIOPHARMA REINFORCES LEADERSHIP IN ENDOCRINOLOGY WITH DATA DISCLOSURES SPANNING COMMERCIAL PORTFOLIO & PIPELINE AT MULTIPLE SCIENTIFIC MEETINGS
Benzinga · Oct 14, 2026
On October 13, 2026, Xeris Biopharma Holdings, Inc. (the "Company"), through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., filed patent infringement lawsuits in the United States District Court for
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XERS.
